A Ten-Week Study Evaluating The Effectiveness And Safety Of Zoloft In Children And Adolescents With A Diagnosis Of PTSD
Public ClinicalTrials.gov record NCT00150306. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, 10-Week, Randomized, Double-Blind Study Of Sertraline And Placebo In Children And Adolescents With Posttraumatic Stress Disorder (PTSD)
Study identification
- NCT ID
- NCT00150306
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Interventions
- Zoloft (Sertraline) Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2002
- Primary completion
- Not listed
- Completion
- Jun 30, 2007
- Last update posted
- Jan 28, 2021
2002 – 2007
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Scottsdale | Arizona | 85281 | — |
| Pfizer Investigational Site | Sacramento | California | 95817 | — |
| Pfizer Investigational Site | San Diego | California | 92111 | — |
| Pfizer Investigational Site | San Marcos | California | 92078 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32611 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46202-5200 | — |
| Pfizer Investigational Site | Terre Haute | Indiana | 47802 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66214 | — |
| Pfizer Investigational Site | Baton Rouge | Louisiana | 70816 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70112 | — |
| Pfizer Investigational Site | Bethesda | Maryland | 20814 | — |
| Pfizer Investigational Site | Las Vegas | Nevada | 89128 | — |
| Pfizer Investigational Site | Lebanon | New Hampshire | 03756-0002 | — |
| Pfizer Investigational Site | Manhasset | New York | 11030 | — |
| Pfizer Investigational Site | New York | New York | 10016 | — |
| Pfizer Investigational Site | Stony Brook | New York | 11794 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44106 | — |
| Pfizer Investigational Site | Lyndhurst | Ohio | 44124 | — |
| Pfizer Investigational Site | Charleston | South Carolina | 29425 | — |
| Pfizer Investigational Site | Galveston | Texas | 77555-0188 | — |
| Pfizer Investigational Site | Houston | Texas | 77058 | — |
| Pfizer Investigational Site | Plano | Texas | 75024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00150306, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2021 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00150306 live on ClinicalTrials.gov.